Provectus PV-10 Phase 2 trial data on metastatic melanoma to be presented at two conferences

Jun 16 2011

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at two upcoming melanoma conferences.

On June 21, 2011, Dr. Sanjiv Agarwala, Chief of Medical Oncology and Hematology at St. Luke's Hospital and Health Network in Bethlehem, PA and Principal Investigator for our Phase 2 trial site at St. Luke's, will deliver an oral presentation at the 7^th EADO (European Association of Dermato-Oncology) Conference in Nantes, France. His presentation, entitled, "Chemoablation of Metastatic Melanoma with Intralesional PV-10," will begin at 2:20 p.m. local time.

On June 25, 2011, Professor Merrick Ross, M.D. of the MD Anderson Cancer Center in Houston, Texas, will be presenting at the HemOnc Today Conference in New York City. His presentation, entitled "Intralesional Therapy for Systemic Disease: Implications for Success and Failure," will begin at 2:20 p.m. local time.

Dr. Craig Dees, PhD, CEO of Provectus said, "At each of these conferences, investigators for our PV-10 program will provide further data from the Phase 2 trial of PV-10 for metastatic melanoma. We look forward to the opportunities to present these data to both an international and domestic audience, as we prepare for a multi-center, global Phase 3 trial."

Source: Provectus Pharmaceuticals, Inc.